AR120652A1 - Antagonistas de sstr5 - Google Patents
Antagonistas de sstr5Info
- Publication number
- AR120652A1 AR120652A1 ARP200103345A ARP200103345A AR120652A1 AR 120652 A1 AR120652 A1 AR 120652A1 AR P200103345 A ARP200103345 A AR P200103345A AR P200103345 A ARP200103345 A AR P200103345A AR 120652 A1 AR120652 A1 AR 120652A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluoroalkyl
- cycloalkyl
- membered heterocycloalkyl
- halogen
- Prior art date
Links
- 101000829153 Homo sapiens Somatostatin receptor type 5 Proteins 0.000 title abstract 2
- 102100023806 Somatostatin receptor type 5 Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 12
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- YMANQWHUUFJQOW-UHFFFAOYSA-N 1,2-diazaspiro[4.5]decane Chemical compound N1NCCC11CCCCC1 YMANQWHUUFJQOW-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007149 gut brain axis pathway Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943099P | 2019-12-03 | 2019-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120652A1 true AR120652A1 (es) | 2022-03-09 |
Family
ID=76221934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103345A AR120652A1 (es) | 2019-12-03 | 2020-12-02 | Antagonistas de sstr5 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230041621A1 (https=) |
| EP (3) | EP4069702A4 (https=) |
| JP (1) | JP2023516235A (https=) |
| CN (1) | CN115380036A (https=) |
| AR (1) | AR120652A1 (https=) |
| AU (1) | AU2020398874A1 (https=) |
| CA (1) | CA3163243A1 (https=) |
| TW (1) | TW202134248A (https=) |
| UY (1) | UY38976A (https=) |
| WO (3) | WO2021113363A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| CN116789570B (zh) * | 2022-03-14 | 2026-01-27 | 长沙理工大学 | 磺酰胺脱氨制备磺酸衍生物的方法 |
| WO2024204277A1 (ja) | 2023-03-27 | 2024-10-03 | 株式会社スコヒアファーマ | 成長ホルモン分泌促進剤 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025222008A1 (en) * | 2024-04-19 | 2025-10-23 | Eli Lilly And Company | Glucagon receptor agonists and their use as therapies |
| WO2025222000A1 (en) * | 2024-04-19 | 2025-10-23 | Eli Lilly And Company | Substituted 1,1'-biphenyl compounds as glucagon receptor agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458374A2 (en) * | 2001-12-14 | 2004-09-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| EP1786815B1 (en) * | 2003-09-10 | 2011-08-24 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
| US7709642B2 (en) * | 2004-06-25 | 2010-05-04 | Virochem Pharma, Inc. | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| JP2009502786A (ja) * | 2005-07-18 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病を治療するためのスピロピペリジンβ−セクレターゼ阻害剤 |
| WO2008019967A2 (en) * | 2006-08-15 | 2008-02-21 | F. Hoffmann-La Roche Ag | Phenyl, pyridine and quinoline derivatives |
| US20100298342A1 (en) * | 2006-09-07 | 2010-11-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease |
| TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| JP2012526136A (ja) * | 2009-05-07 | 2012-10-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物として有用な置換スピロ環式アミン |
| JPWO2011142359A1 (ja) * | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| AU2011256444B2 (en) * | 2010-05-18 | 2014-07-10 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as SSTR5 antagonists |
| WO2012024183A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| TW201712012A (zh) * | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
-
2020
- 2020-12-02 WO PCT/US2020/062891 patent/WO2021113363A1/en not_active Ceased
- 2020-12-02 EP EP20895271.3A patent/EP4069702A4/en not_active Withdrawn
- 2020-12-02 JP JP2022529942A patent/JP2023516235A/ja active Pending
- 2020-12-02 CA CA3163243A patent/CA3163243A1/en active Pending
- 2020-12-02 US US17/782,361 patent/US20230041621A1/en not_active Abandoned
- 2020-12-02 AU AU2020398874A patent/AU2020398874A1/en not_active Abandoned
- 2020-12-02 WO PCT/US2020/062890 patent/WO2021113362A1/en not_active Ceased
- 2020-12-02 EP EP20896919.6A patent/EP4073075A4/en not_active Withdrawn
- 2020-12-02 US US17/782,438 patent/US20230113609A1/en not_active Abandoned
- 2020-12-02 WO PCT/US2020/062898 patent/WO2021113368A1/en not_active Ceased
- 2020-12-02 UY UY0001038976A patent/UY38976A/es not_active Application Discontinuation
- 2020-12-02 US US17/782,370 patent/US20230050965A1/en not_active Abandoned
- 2020-12-02 EP EP20895270.5A patent/EP4069708A4/en not_active Withdrawn
- 2020-12-02 CN CN202080095492.0A patent/CN115380036A/zh active Pending
- 2020-12-02 AR ARP200103345A patent/AR120652A1/es unknown
- 2020-12-03 TW TW109142680A patent/TW202134248A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021113363A1 (en) | 2021-06-10 |
| EP4069702A1 (en) | 2022-10-12 |
| AU2020398874A1 (en) | 2022-06-23 |
| EP4069708A4 (en) | 2024-03-20 |
| JP2023516235A (ja) | 2023-04-19 |
| WO2021113362A1 (en) | 2021-06-10 |
| EP4073075A1 (en) | 2022-10-19 |
| CA3163243A1 (en) | 2021-06-10 |
| EP4069702A4 (en) | 2023-12-27 |
| UY38976A (es) | 2021-06-30 |
| EP4073075A4 (en) | 2023-12-27 |
| WO2021113368A1 (en) | 2021-06-10 |
| CN115380036A (zh) | 2022-11-22 |
| US20230041621A1 (en) | 2023-02-09 |
| TW202134248A (zh) | 2021-09-16 |
| US20230050965A1 (en) | 2023-02-16 |
| US20230113609A1 (en) | 2023-04-13 |
| EP4069708A1 (en) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120652A1 (es) | Antagonistas de sstr5 | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR117616A1 (es) | Compuestos anti-vih | |
| JP2018526367A5 (https=) | ||
| AR110346A1 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR105575A1 (es) | COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| ECSP12011695A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| MX379057B (es) | Compuestos de benzoxaborol y uso de los mismos. | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |